← Back to Screener
Moderna, Inc. Common Stock (MRNA)
Price$46.06
Value ScoreC
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)95.12%
Price vs S&P 500 (4W)-0.96%
VGM Score55.58
Market Capitalization$18.72B
All Metrics
Book Value / Share (Quarterly)$18.66
P/TBV (Annual)1.34x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-53.44%
Cash Flow / Share (Quarterly)$-4.04
Price vs S&P 500 (YTD)49.09%
Gross Margin (TTM)35.01%
Net Profit Margin (TTM)-143.55%
EPS (TTM)$-8.15
10-Day Avg Trading Volume5.02M
EPS Excl Extra (TTM)$-8.15
Revenue Growth (5Y)19.34%
EPS (Annual)$-7.25
ROI (Annual)-30.39%
Gross Margin (Annual)70.32%
Net Profit Margin (5Y Avg)-42.91%
Cash / Share (Quarterly)$13.11
Revenue Growth QoQ (YoY)260.19%
ROA (Last FY)-22.87%
Revenue Growth TTM (YoY)-29.97%
EBITD / Share (TTM)$-8.12
ROE (5Y Avg)6.13%
Operating Margin (TTM)-153.35%
Cash Flow / Share (Annual)$-5.27
P/B Ratio2.53x
P/B Ratio (Quarterly)2.72x
Net Income / Employee (Annual)$-600,400
EV / Revenue (TTM)7.84x
ROA (TTM)-26.63%
EV / EBITDA (TTM)19.92x
EPS Incl Extra (Annual)$-7.25
Current Ratio (Annual)3.29x
Quick Ratio (Quarterly)2.26x
3-Month Avg Trading Volume8.86M
52-Week Price Return75.23%
EV / Free Cash Flow (Annual)2.54x
Revenue / Employee (TTM)$473,400
Tangible BV / Share (Quarterly)$18.37
P/S Ratio (Annual)9.63x
Asset Turnover (Annual)0.16x
52-Week High$59.55
Operating Margin (5Y Avg)-44.21%
EPS Excl Extra (Annual)$-7.25
CapEx CAGR (5Y)24.70%
Tangible BV CAGR (5Y)98.20%
26-Week Price Return111.05%
Quick Ratio (Annual)3.08x
13-Week Price Return-8.74%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)2.41x
Enterprise Value$17.45B
Revenue / Share Growth (5Y)18.85%
Asset Turnover (TTM)0.19x
Book Value / Share Growth (5Y)27.87%
Revenue / Employee (Annual)$413,600
Inventory Turnover (Annual)4.27x
Pretax Margin (Annual)-142.39%
Cash / Share (Annual)$14.72
3-Month Return Std Dev62.19%
Gross Margin (5Y Avg)72.34%
Net Income / Employee (TTM)$-679,600
ROE (Last FY)-32.62%
EPS Basic Excl Extra (Annual)$-7.25
P/FCF (TTM)21.02x
Receivables Turnover (TTM)29.87x
Total Debt / Equity (Quarterly)0.09x
EPS Incl Extra (TTM)$-8.15
Receivables Turnover (Annual)7.17x
ROI (TTM)-35.32%
P/S Ratio (TTM)8.42x
Pretax Margin (5Y Avg)-37.96%
Revenue / Share (Annual)$5.00
Tangible BV / Share (Annual)$21.84
Price vs S&P 500 (52W)47.03%
Year-to-Date Return60.02%
5-Day Price Return0.66%
EPS Normalized (Annual)$-7.25
ROA (5Y Avg)1.63%
Net Profit Margin (Annual)-145.16%
Month-to-Date Return2.72%
Cash Flow / Share (TTM)$-7.54
EBITD / Share (Annual)$-7.35
Operating Margin (Annual)-158.13%
LT Debt / Equity (Annual)0.07x
ROI (5Y Avg)5.54%
LT Debt / Equity (Quarterly)0.08x
EPS Basic Excl Extra (TTM)$-8.15
P/TBV (Quarterly)2.76x
P/B Ratio (Annual)1.33x
Inventory Turnover (TTM)10.55x
Pretax Margin (TTM)-141.03%
Book Value / Share (Annual)$21.95
Price vs S&P 500 (13W)-18.49%
Beta1.03x
P/FCF (Annual)4.09x
Revenue / Share (TTM)$5.63
ROE (TTM)-36.73%
52-Week Low$22.28
vGradeC
gGradeB
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-3.40est. -4.04
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.80
2.80
2.80
3.23
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
| TECHBio-Techne Corp. | D | C | C | $50.79 |
About
Moderna is a biotechnology company leveraging its validated mRNA platform to develop therapeutics across infectious disease, oncology, cardiovascular disease, and rare genetic diseases. The company commercially validated its technology with its FDA-authorized COVID-19 vaccine in 2020. As of August 2025, Moderna maintains a pipeline of 35 mRNA candidates in clinical development.